The University of Chicago Header Logo

Connection

Stephen Hanauer to Crohn Disease

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Crohn Disease.
Stephen Hanauer
Connection Strength
27.230
Crohn Disease
  1. The position of anti-tumor necrosis factor agents for the treatment of adult patients with Crohn's disease. Expert Rev Gastroenterol Hepatol. 2025 Jul; 19(7):725-743.
    View in: PubMed
    Score: 0.574
  2. Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). J Crohns Colitis. 2025 Jun 04; 19(6).
    View in: PubMed
    Score: 0.571
  3. Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine. Expert Rev Clin Immunol. 2025 Apr; 21(4):461-472.
    View in: PubMed
    Score: 0.558
  4. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.
    View in: PubMed
    Score: 0.532
  5. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533.
    View in: PubMed
    Score: 0.516
  6. EXPLORing the Therapeutic Ceiling in Crohn's Disease: Will Combination Pave the Way? Clin Gastroenterol Hepatol. 2024 Jul; 22(7):1377-1378.
    View in: PubMed
    Score: 0.514
  7. The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Jul-Dec; 19(9):1075-1089.
    View in: PubMed
    Score: 0.496
  8. Hospitalization Experiences and Post-traumatic Stress in Inflammatory Bowel Disease: Opportunities for Change. Inflamm Bowel Dis. 2023 05 02; 29(5):675-683.
    View in: PubMed
    Score: 0.494
  9. Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease. Immunotherapy. 2022 12; 14(17):1353-1359.
    View in: PubMed
    Score: 0.481
  10. Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes. Inflamm Bowel Dis. 2022 05 04; 28(5):710-719.
    View in: PubMed
    Score: 0.461
  11. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 10; 6(10):816-825.
    View in: PubMed
    Score: 0.438
  12. Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape. Curr Gastroenterol Rep. 2021 Aug 02; 23(9):16.
    View in: PubMed
    Score: 0.438
  13. Which Diet for Crohn's Disease? Food for Thought on the Specific Carbohydrate Diet, Mediterranean Diet, and Beyond. Gastroenterology. 2021 09; 161(3):798-800.
    View in: PubMed
    Score: 0.435
  14. Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2020 11 19; 26(12):1808-1818.
    View in: PubMed
    Score: 0.417
  15. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32.
    View in: PubMed
    Score: 0.392
  16. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42.
    View in: PubMed
    Score: 0.358
  17. A Never Ending STORI. Clin Gastroenterol Hepatol. 2018 07; 16(7):1034-1036.
    View in: PubMed
    Score: 0.343
  18. Targeting Crohn's disease. Lancet. 2017 12 23; 390(10114):2742-2744.
    View in: PubMed
    Score: 0.337
  19. Optimizing pharmacologic management of inflammatory bowel disease. Expert Rev Clin Pharmacol. 2017 Jun; 10(6):595-607.
    View in: PubMed
    Score: 0.326
  20. Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient. Lancet. 2017 04 29; 389(10080):1671-1672.
    View in: PubMed
    Score: 0.325
  21. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.309
  22. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870.
    View in: PubMed
    Score: 0.308
  23. Hyperacute Methotrexate Pneumonitis in a Patient With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):A29-30.
    View in: PubMed
    Score: 0.295
  24. The Holy Grail, or only half way there? Gastroenterology. 2015 Jan; 148(1):8-10.
    View in: PubMed
    Score: 0.275
  25. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1464-78.e1-5.
    View in: PubMed
    Score: 0.257
  26. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther. 2014 Jan; 39(2):163-75.
    View in: PubMed
    Score: 0.257
  27. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63.
    View in: PubMed
    Score: 0.249
  28. Reassessing the risks and benefits of thiopurines in Crohn's disease. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):395-7.
    View in: PubMed
    Score: 0.242
  29. What to take from TREAT? Am J Gastroenterol. 2012 Sep; 107(9):1423-5.
    View in: PubMed
    Score: 0.236
  30. Association between higher predicted serum vitamin D levels and reduced incidence of inflammatory bowel diseases. Gastroenterology. 2012 Sep; 143(3):e28.
    View in: PubMed
    Score: 0.234
  31. Treat the patient or treat the disease? Dig Dis. 2012; 30(4):400-3.
    View in: PubMed
    Score: 0.234
  32. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut. 2013 Sep; 62(9):1288-94.
    View in: PubMed
    Score: 0.233
  33. Complications of peristomal recurrence of Crohn's disease: a case report and a review of literature. J Wound Ostomy Continence Nurs. 2012 May-Jun; 39(3):297-301.
    View in: PubMed
    Score: 0.230
  34. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul; 143(1):62-69.e4.
    View in: PubMed
    Score: 0.230
  35. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med. 2011 Apr; 124(4 Suppl):e1-18.
    View in: PubMed
    Score: 0.214
  36. Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis. 2011 Nov; 17(11):2366-91.
    View in: PubMed
    Score: 0.212
  37. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010 Dec 08; (12):CD008870.
    View in: PubMed
    Score: 0.209
  38. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease. J Crohns Colitis. 2011 Feb; 5(1):48-53.
    View in: PubMed
    Score: 0.207
  39. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93.
    View in: PubMed
    Score: 0.201
  40. Medical management of Crohn's disease: treatment algorithms 2009. Dig Dis. 2009; 27(4):536-41.
    View in: PubMed
    Score: 0.194
  41. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis. 2009 Oct; 15(10):1570-82.
    View in: PubMed
    Score: 0.193
  42. More likely than not. Nat Clin Pract Gastroenterol Hepatol. 2007 Sep; 4(9):469.
    View in: PubMed
    Score: 0.167
  43. European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut. 2007 Feb; 56(2):161-3.
    View in: PubMed
    Score: 0.160
  44. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan; 13(1):2-11.
    View in: PubMed
    Score: 0.159
  45. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2.
    View in: PubMed
    Score: 0.159
  46. Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord. 2007; 7 Suppl 2:S17-22.
    View in: PubMed
    Score: 0.159
  47. "Hit me with your best shot... Fire away!". Nat Clin Pract Gastroenterol Hepatol. 2006 Sep; 3(9):473.
    View in: PubMed
    Score: 0.156
  48. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9.
    View in: PubMed
    Score: 0.154
  49. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006 Mar; 63(3):433-42; quiz 464.
    View in: PubMed
    Score: 0.150
  50. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591.
    View in: PubMed
    Score: 0.150
  51. Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov; 2(11):493.
    View in: PubMed
    Score: 0.147
  52. Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. Inflamm Bowel Dis. 2025 Oct 01; 31(10):2714-2724.
    View in: PubMed
    Score: 0.146
  53. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease. Am J Gastroenterol. 2005 Jul; 100(7):1438-9.
    View in: PubMed
    Score: 0.144
  54. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis. 2005 Jun; 11(6):609-12.
    View in: PubMed
    Score: 0.143
  55. Treatment of Crohn's disease: the "long" of it. Gastroenterology. 2005 Jun; 128(7):2164-6.
    View in: PubMed
    Score: 0.143
  56. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005 May-Jun; 39(5):390-5.
    View in: PubMed
    Score: 0.142
  57. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):363-71.
    View in: PubMed
    Score: 0.140
  58. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84.
    View in: PubMed
    Score: 0.140
  59. Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116.
    View in: PubMed
    Score: 0.138
  60. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:60-5.
    View in: PubMed
    Score: 0.136
  61. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9.
    View in: PubMed
    Score: 0.136
  62. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am J Gastroenterol. 2004 Aug; 99(8):1523-6.
    View in: PubMed
    Score: 0.135
  63. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul; 2(7):542-53.
    View in: PubMed
    Score: 0.134
  64. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am. 2004 Jun; 33(2):303-17, ix-x.
    View in: PubMed
    Score: 0.133
  65. Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2024 May 31; 18(5):708-719.
    View in: PubMed
    Score: 0.133
  66. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004 May; 2(5):379-88.
    View in: PubMed
    Score: 0.132
  67. Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. J Crohns Colitis. 2024 Apr 23; 18(4):493-505.
    View in: PubMed
    Score: 0.132
  68. Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease. Dig Dis Sci. 2024 Jun; 69(6):2044-2054.
    View in: PubMed
    Score: 0.132
  69. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004 Feb; 126(2):402-13.
    View in: PubMed
    Score: 0.130
  70. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004 Jan; 99(1):91-6.
    View in: PubMed
    Score: 0.129
  71. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(2):66-85.
    View in: PubMed
    Score: 0.129
  72. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(3):104-17.
    View in: PubMed
    Score: 0.129
  73. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24.
    View in: PubMed
    Score: 0.129
  74. Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study. J Crohns Colitis. 2023 Dec 30; 17(12):1897-1909.
    View in: PubMed
    Score: 0.129
  75. Considerations in the management of steroid-dependent Crohn's disease. Gastroenterology. 2003 Sep; 125(3):906-10.
    View in: PubMed
    Score: 0.126
  76. The importance of predicting patient responses to monoclonal antibodies for Crohn's disease. Expert Opin Biol Ther. 2023 Jul-Dec; 23(10):941-949.
    View in: PubMed
    Score: 0.126
  77. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024 01; 22(1):144-153.e2.
    View in: PubMed
    Score: 0.125
  78. Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 2003 May 22; 348(21):2155-6; author reply 2155-6.
    View in: PubMed
    Score: 0.124
  79. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003 May; 9(3):176-8.
    View in: PubMed
    Score: 0.124
  80. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):131-7.
    View in: PubMed
    Score: 0.121
  81. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72.
    View in: PubMed
    Score: 0.120
  82. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2023 04; 21(4):878-890.
    View in: PubMed
    Score: 0.119
  83. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
    View in: PubMed
    Score: 0.117
  84. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211.
    View in: PubMed
    Score: 0.116
  85. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 04; 359(9317):1541-9.
    View in: PubMed
    Score: 0.115
  86. Medical treatment of Crohn's disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):167-84, x.
    View in: PubMed
    Score: 0.114
  87. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 06; 162(7):1876-1890.
    View in: PubMed
    Score: 0.113
  88. The smoke is clearing in Crohn's disease. Curr Gastroenterol Rep. 2001 Dec; 3(6):456-7.
    View in: PubMed
    Score: 0.112
  89. Crohn's disease therapy: step up or top down therapy. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):189-90.
    View in: PubMed
    Score: 0.107
  90. Biologics in peri-operative management of Crohn's disease. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):191-2.
    View in: PubMed
    Score: 0.107
  91. Management of Crohn's disease in adults. Am J Gastroenterol. 2001 Mar; 96(3):635-43.
    View in: PubMed
    Score: 0.106
  92. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4.
    View in: PubMed
    Score: 0.106
  93. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77.
    View in: PubMed
    Score: 0.104
  94. Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study. Int J Cancer. 2020 11 15; 147(10):2735-2742.
    View in: PubMed
    Score: 0.101
  95. Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol. 2000 May; 95(5):1139-46.
    View in: PubMed
    Score: 0.100
  96. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7.
    View in: PubMed
    Score: 0.097
  97. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999 Sep; 13 Suppl 4:16-22; discussion 38.
    View in: PubMed
    Score: 0.096
  98. Updating the approach to Crohn's disease. Hosp Pract (1995). 1999 Aug 15; 34(8):77-8, 81-3, 87-93; discussion 94.
    View in: PubMed
    Score: 0.095
  99. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33.
    View in: PubMed
    Score: 0.094
  100. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998 Oct; 93(10):1867-72.
    View in: PubMed
    Score: 0.090
  101. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1.
    View in: PubMed
    Score: 0.090
  102. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998 Sep-Oct; 20(5):1009-28.
    View in: PubMed
    Score: 0.089
  103. Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study. Inflamm Bowel Dis. 2018 08 16; 24(9):2001-2006.
    View in: PubMed
    Score: 0.089
  104. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77.
    View in: PubMed
    Score: 0.088
  105. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 05; 154(6):1660-1671.
    View in: PubMed
    Score: 0.086
  106. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.085
  107. Medical management of perianal Crohn's disease. Semin Gastrointest Dis. 1998 Jan; 9(1):10-4.
    View in: PubMed
    Score: 0.085
  108. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228.
    View in: PubMed
    Score: 0.085
  109. Management of Crohn's disease in adults. Am J Gastroenterol. 1997 Apr; 92(4):559-66.
    View in: PubMed
    Score: 0.081
  110. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960.
    View in: PubMed
    Score: 0.079
  111. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 11; 22(11):2711-2723.
    View in: PubMed
    Score: 0.079
  112. Development of an index to define overall disease severity in IBD. Gut. 2018 02; 67(2):244-254.
    View in: PubMed
    Score: 0.079
  113. Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. Inflamm Bowel Dis. 2016 May; 22(5):1168-83.
    View in: PubMed
    Score: 0.076
  114. Inflammatory bowel disease. N Engl J Med. 1996 Mar 28; 334(13):841-8.
    View in: PubMed
    Score: 0.076
  115. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578.
    View in: PubMed
    Score: 0.075
  116. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.075
  117. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9.
    View in: PubMed
    Score: 0.075
  118. Review article: the medical management of Crohn's disease. Aliment Pharmacol Ther. 1996 Feb; 10(1):1-22.
    View in: PubMed
    Score: 0.075
  119. Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflamm Bowel Dis. 2015 Aug; 21(8):1809-16.
    View in: PubMed
    Score: 0.072
  120. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40.
    View in: PubMed
    Score: 0.071
  121. Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease. Gut. 1995 May; 36(5):715-7.
    View in: PubMed
    Score: 0.071
  122. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.068
  123. Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):1981-90.
    View in: PubMed
    Score: 0.068
  124. In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. J Crohns Colitis. 2014 Nov; 8(11):1539-47.
    View in: PubMed
    Score: 0.067
  125. Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4.
    View in: PubMed
    Score: 0.067
  126. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3.
    View in: PubMed
    Score: 0.066
  127. AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study. Inflamm Bowel Dis. 2014 May; 20(5):872-81.
    View in: PubMed
    Score: 0.066
  128. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014 Nov; 63(11):1721-7.
    View in: PubMed
    Score: 0.065
  129. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.064
  130. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2.
    View in: PubMed
    Score: 0.063
  131. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993 Sep; 88(9):1343-51.
    View in: PubMed
    Score: 0.063
  132. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21.
    View in: PubMed
    Score: 0.063
  133. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993 May; 88(5):646-9.
    View in: PubMed
    Score: 0.062
  134. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013 Apr; 19(5):1073-9.
    View in: PubMed
    Score: 0.061
  135. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.061
  136. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):754-60.
    View in: PubMed
    Score: 0.061
  137. Crohn's disease. Curr Probl Surg. 1993 Feb; 30(2):173-265.
    View in: PubMed
    Score: 0.061
  138. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
    View in: PubMed
    Score: 0.061
  139. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28.
    View in: PubMed
    Score: 0.060
  140. Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5.
    View in: PubMed
    Score: 0.058
  141. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
    View in: PubMed
    Score: 0.057
  142. Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath? Gastroenterology. 1991 Oct; 101(4):1130-1.
    View in: PubMed
    Score: 0.055
  143. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17.
    View in: PubMed
    Score: 0.054
  144. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26.
    View in: PubMed
    Score: 0.053
  145. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.053
  146. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther. 2011 May; 33(10):1143-51.
    View in: PubMed
    Score: 0.053
  147. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr; 106(4):685-98.
    View in: PubMed
    Score: 0.053
  148. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660.
    View in: PubMed
    Score: 0.053
  149. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93.
    View in: PubMed
    Score: 0.052
  150. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213.
    View in: PubMed
    Score: 0.052
  151. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1.
    View in: PubMed
    Score: 0.050
  152. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9.
    View in: PubMed
    Score: 0.049
  153. The role of mesalazine in Crohn's disease. Scand J Gastroenterol Suppl. 1990; 172:56-9.
    View in: PubMed
    Score: 0.049
  154. Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study. Gastroenterology. 1989 Dec; 97(6):1442-7.
    View in: PubMed
    Score: 0.049
  155. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009 Aug; 104(8):2089-96.
    View in: PubMed
    Score: 0.047
  156. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36.
    View in: PubMed
    Score: 0.047
  157. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
    View in: PubMed
    Score: 0.047
  158. Preoperative total parenteral nutrition for bowel resection in Crohn's disease. Dig Dis Sci. 1989 May; 34(5):741-6.
    View in: PubMed
    Score: 0.047
  159. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol. 2009 Mar 20; 9:22.
    View in: PubMed
    Score: 0.046
  160. Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb; 104(2):465-83; quiz 464, 484.
    View in: PubMed
    Score: 0.046
  161. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31.
    View in: PubMed
    Score: 0.045
  162. Mea culpa. Nat Clin Pract Gastroenterol Hepatol. 2008 Aug; 5(8):409.
    View in: PubMed
    Score: 0.044
  163. Smoking and inflammatory bowel disease in families. Am J Gastroenterol. 1988 Apr; 83(4):407-9.
    View in: PubMed
    Score: 0.043
  164. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3.
    View in: PubMed
    Score: 0.042
  165. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Sep; 45(3):312-8.
    View in: PubMed
    Score: 0.042
  166. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50.
    View in: PubMed
    Score: 0.041
  167. Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts. Inflamm Bowel Dis. 2007 May; 13(5):573-9.
    View in: PubMed
    Score: 0.041
  168. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38.
    View in: PubMed
    Score: 0.041
  169. Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease. Ann Behav Med. 2007 Apr; 33(2):207-12.
    View in: PubMed
    Score: 0.041
  170. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9.
    View in: PubMed
    Score: 0.040
  171. Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S3-10.
    View in: PubMed
    Score: 0.040
  172. Prevalence and incidence of inflammatory bowel disease in family members. Gastroenterology. 1986 Dec; 91(6):1396-400.
    View in: PubMed
    Score: 0.040
  173. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65.
    View in: PubMed
    Score: 0.040
  174. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8.
    View in: PubMed
    Score: 0.038
  175. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006 May; 101(5):1012-23.
    View in: PubMed
    Score: 0.038
  176. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25.
    View in: PubMed
    Score: 0.037
  177. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7.
    View in: PubMed
    Score: 0.036
  178. Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285.
    View in: PubMed
    Score: 0.036
  179. The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease. Inflamm Bowel Dis. 2024 11 04; 30(11):2064-2075.
    View in: PubMed
    Score: 0.034
  180. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
    View in: PubMed
    Score: 0.034
  181. Crohn's disease. The problem and its management. Hosp Pract (Off Ed). 1984 Jul; 19(7):121-32, 135-6, 141-2.
    View in: PubMed
    Score: 0.033
  182. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S11-21.
    View in: PubMed
    Score: 0.033
  183. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10.
    View in: PubMed
    Score: 0.033
  184. Selected individual therapeutic problems in inflammatory bowel disease. Am J Gastroenterol. 1984 May; 79(5):368-75.
    View in: PubMed
    Score: 0.033
  185. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov; 125(5):1508-30.
    View in: PubMed
    Score: 0.032
  186. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003 Sep; 9(5):281-9.
    View in: PubMed
    Score: 0.032
  187. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug; 125(2):380-8.
    View in: PubMed
    Score: 0.031
  188. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
    View in: PubMed
    Score: 0.030
  189. New steroids for IBD: progress report. Gut. 2002 Aug; 51(2):182-3.
    View in: PubMed
    Score: 0.029
  190. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002 Jul; 97(7):1748-54.
    View in: PubMed
    Score: 0.029
  191. Acute leukemia following inflammatory bowel disease. Dig Dis Sci. 1982 Jun; 27(6):545-8.
    View in: PubMed
    Score: 0.029
  192. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb; 122(2):512-30.
    View in: PubMed
    Score: 0.028
  193. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov; 121(5):1088-94.
    View in: PubMed
    Score: 0.028
  194. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001 May 31; 411(6837):603-6.
    View in: PubMed
    Score: 0.027
  195. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8.
    View in: PubMed
    Score: 0.027
  196. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001 Jan; 15(1):35-44.
    View in: PubMed
    Score: 0.026
  197. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1461-72.
    View in: PubMed
    Score: 0.026
  198. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1473-82.
    View in: PubMed
    Score: 0.026
  199. Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology. 2000 Dec; 119(6):1483-90.
    View in: PubMed
    Score: 0.026
  200. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000 Nov; 95(11):3150-6.
    View in: PubMed
    Score: 0.026
  201. Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study. Ann Surg. 2000 Sep; 232(3):401-8.
    View in: PubMed
    Score: 0.026
  202. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000 Jun 01; 342(22):1627-32.
    View in: PubMed
    Score: 0.025
  203. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000 Feb; 6(1):8-15.
    View in: PubMed
    Score: 0.025
  204. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999 Oct; 117(4):761-9.
    View in: PubMed
    Score: 0.024
  205. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999 Sep; 117(3):527-35.
    View in: PubMed
    Score: 0.024
  206. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology. 1999 Jul; 117(1):58-64.
    View in: PubMed
    Score: 0.024
  207. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):297-321.
    View in: PubMed
    Score: 0.024
  208. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 06; 340(18):1398-405.
    View in: PubMed
    Score: 0.023
  209. American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology. 1998 Nov; 115(5):1056-61.
    View in: PubMed
    Score: 0.023
  210. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A. 1998 Jun 23; 95(13):7502-7.
    View in: PubMed
    Score: 0.022
  211. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 09; 337(15):1029-35.
    View in: PubMed
    Score: 0.021
  212. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci. 1995 May; 40(5):931-5.
    View in: PubMed
    Score: 0.018
  213. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May; 104(5):1293-301.
    View in: PubMed
    Score: 0.015
  214. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol. 1993 Mar; 88(3):356-9.
    View in: PubMed
    Score: 0.015
  215. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991 Sep; 32(9):1071-5.
    View in: PubMed
    Score: 0.014
  216. Cigarette smoking in Crohn's disease. Am J Gastroenterol. 1989 Jan; 84(1):31-3.
    View in: PubMed
    Score: 0.011
  217. Acute pancreatitis associated with high-concentration lipid emulsion during total parenteral nutrition therapy for Crohn's disease. Gastroenterology. 1986 Apr; 90(4):1039-41.
    View in: PubMed
    Score: 0.009
  218. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am J Gastroenterol. 2006 Mar; 101(3):572-80.
    View in: PubMed
    Score: 0.009
  219. Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology. 1985 Jan-Feb; 5(1):79-84.
    View in: PubMed
    Score: 0.009
  220. Circulating lymphocyte subpopulations in Crohn's disease. Gastroenterology. 1983 Dec; 85(6):1313-8.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.